Bristol-Myers Squibb (BMY) – Reuters
-
J&J, Bristol Myers lose challenges to US drug price negotiation program
-
Bristol Myers posts quarterly loss, lays out $1.5 billion cost-saving plan
-
Bristol Myers signs $380 million CAR-T therapies supply deal with Cellares
-
Bristol Myers' bowel disease drug fails in late-stage study
-
US FDA staff raises concerns over data from J&J, Bristol's CAR-T therapies
-
Bristol Myers CEO sees mid-decade transition, late decade growth
-
Bristol Myers expects to launch 16 new products through 2030 - CEO
-
Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push
-
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion
-
Bristol Myers says it needs another year to hit target for new drugs
-
Bristol Myers plans to double experimental treatments to expand research pipeline
-
Bristol Myers sales fall, cuts 2023 forecast as drugs face competition
-
Bristol Myers looks to new CEO as competition from generic drugs heats up
-
Bristol Myers CEO Caforio to step down
-
Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal
-
Bristol Myers 1st-quarter sales up on Eliquis, Opdivo
-
Buffett's Berkshire bought Activision shares before Microsoft takeover
-
Bristol Myers posts slightly better-than-expected 4th-qtr results
-
Buffett's Berkshire cuts U.S. drugmaker stakes, invests in drug royalty company
-
U.S. FTC okays changes to Bristol Meyers Squibb divestiture agreement
-
Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound
-
Gilead Sciences wins reversal of $1.2 billion award in patent case with Bristol Myers
-
Bristol Myers sees return to growth for Opdivo, tops estimates
-
U.S. FDA approves Bristol Myers' bowel disease treatment
-
Berkshire's bet a bright spot in gloomy year for Big Pharma stocks
-
Bristol Myers expands heart drug business with $13 billion deal for MyoKardia
-
Wall Street gains as markets look to aid package, Nasdaq closes above 11,000
-
AstraZeneca contacted Gilead over potential megamerger: Bloomberg News
-
Bristol Myers to pay bluebird $200 million for future royalties on cancer therapies
-
More drugmakers hike U.S. prices as new year begins
-
Dealmakers eye cross-border M&A recovery as mega mergers roll on
-
Bristol-Myers posts better-than-expected results, Opdivo growth slows
-
Merck sees ongoing Keytruda strength as its sales top $3 billion in quarter
-
Wall Street bounces as trade temperature cools
-
Pfizer to spinoff, merge off-patent drugs unit with Mylan
-
Eliquis, Orencia sales propel Bristol-Myers to strong second quarter
-
Bristol-Myers profit slightly tops Wall Street view on blood thinner sales
-
Trump's attorney general nominee vows to shield Russia probe from politics
-
Wall Street plunges as factory data, Apple warning fuel slowdown fears
-
Bristol-Myers gets $1.6 billion offer for French consumer health unit
-
Wall Street reverses losses after White House adviser's trade remarks
-
Merck, Bristol-Myers profits rise on cancer drug sales
-
Bristol-Myers to invest in Compugen, collaborate in clinical trials
-
Stada, buyout funds in race for Bristol-Myers' French business: sources
-
Amgen profit beats Street view, will not raise prices again in 2018
-
Tech rally helps Wall Street push higher, Nasdaq has record close
-
Caterpillar taps National Grid's Andrew Bonfield as CFO
-
Too many cancer drugs? Crowded market gives investors pause
-
Merck's Keytruda helps lung cancer patients live longer in trial
-
Wall Street ticks up, lifted by Verizon, chipmakers
Back to BMY Stock Lookup
